About Agena bioscience
Agena Bioscience is a leading provider of genetic testing solutions that enable one-day assay turnaround times on a wide variety of targeted genetic tests, including SARS-CoV-2 detection. The company's scalable MassARRAY System is designed to provide accurate and reliable results for research, clinical, and diagnostic applications.
With over 20 years of experience in the field of genetics, Agena Bioscience has established itself as a trusted partner for researchers and clinicians around the world. The company's innovative technology platform allows for high-throughput genotyping and mutation detection with unparalleled accuracy and sensitivity.
One of the key advantages of Agena Bioscience's MassARRAY System is its ability to analyze multiple targets simultaneously using a single sample. This makes it an ideal solution for large-scale studies that require high throughput screening. Additionally, the system can be customized to meet specific research needs by selecting from a range of pre-designed panels or creating custom panels tailored to individual requirements.
The MassARRAY System utilizes advanced mass spectrometry technology to detect genetic variations with exceptional accuracy. This technology enables highly multiplexed assays that can detect up to 10,000 SNPs (single nucleotide polymorphisms) in a single run. The system also offers superior sensitivity compared to other genotyping platforms, making it an ideal choice for detecting low-frequency mutations in cancer samples or other complex genomic regions.
In addition to its core technology platform, Agena Bioscience offers comprehensive support services including assay design and optimization, data analysis software tools, and technical support from experienced scientists. These services are designed to ensure that customers get the most out of their investment in Agena Bioscience's products.
Agena Bioscience has been at the forefront of COVID-19 testing efforts since the beginning of the pandemic. Its MassARRAY SARS-CoV-2 Panel was one of the first commercially available tests for detecting COVID-19 infections using saliva samples instead of nasopharyngeal swabs. This breakthrough test has helped expand access to COVID-19 testing while reducing discomfort associated with traditional swab-based tests.
Overall, Agena Bioscience is committed to providing innovative solutions that enable researchers and clinicians around the world to advance their understanding of genetics and improve patient outcomes through personalized medicine approaches. With its cutting-edge technology platform and comprehensive support services, Agena Bioscience is well-positioned as a leader in this rapidly evolving field.